The risk of myocardial infarction in patients with atrial fibrillation: An unresolved issue

Internal and Emergency Medicine

Volumn 5, Issue 2, 2010, Pages 91-94

  Polimeni, Licia ^a   Perri, Ludovica ^a   Saliola, Mirella ^a   Basili, Stefania ^a   Violi, Francesco ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ATRIAL FIBRILLATION; HOSPITALIZATION; HUMANS; MYOCARDIAL INFARCTION; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 77953363972     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-010-0352-2     Document Type: Editorial

References (29)

1. Fuster V, Rydén LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 27: 1979-2030.
2. Singer DE, Albers GW, Dalen JE et al (2004) Antithrombotic therapy in atrial fibrillation: the Seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126(suppl): 429S-456S.
3. Benjamin EJ, Levy D, Vaziri SM et al (1994) Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271: 840-844.
4. Vizzardi E, Nodari S, Zanini G et al (2009) High sensitivity C-reactive protein: a predictor for recurrence of atrial fibrillation after successful cardioversion. Intern Emerg Med 4: 309-313.
5. Aronow WS, Ahn C, Mercando AD et al (1995) Correlation of atrial fibrillation, paroxysmal supraventricular tachycardia, and sinus rhythm with incidences of new coronary events in 1, 359 patients, mean age 81 years, with heart disease. Am J Cardiol 75: 182-184.
6. Miyasaka Y, Barnes ME et al (2007) Coronary ischemic events after first atrial fibrillation: risk and survival. Am J Med 120: 357-363.
7. Krahn AD, Manfreda J, Tate RB et al (1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98: 476-484.
8. Kaarisalo MM, Immonen-Räihä P et al (1997) Atrial fibrillation and stroke. Mortality and causes of death after the first acute ischemic stroke. Stroke 28: 311-315.
9. Wachtell K, Hornestam B, Lehto M et al (2005) Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45: 705-711.
10. Miyasaka Y, Barnes ME et al (2007) Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol 49: 986-992.
11. Hohnloser SH, Crijns HJ, van Eickels M et al (2009) ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360: 668-678.
12. Haywood LJ, Ford CE, Crow RS et al (2009) Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol 54: 2023-2031.
13. Morocutti C, Amabile G, Fattapposta F et al (1997) Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Stroke 28: 1015-1021.
14. Olsson SB, Executive Steering Committee of the SPORTIF III Investigators (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 362: 1691-1698.
15. Executive Steering Committee for the SPORTIF V Investigators (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. JAMA 293: 690-698.
16. Mant J, Hobbs FD, Fletcher K et al (2007) BAFTA investigators; Midland Research Practices Network (MidReC). Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370: 493-503.
17. Connolly SJ, Ezekowitz MD et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
18. Ford ES, Giles WH et al (2000) Prevalence of nonfatal coronary heart disease among American adults. Am Heart J 139: 371-377.
19. Pan NH, Tsao HM, Chang NC et al (2009) Dilated left atrium and pulmonary veins in patients with calcified coronary artery: a potential contributor to the genesis of atrial fibrillation. J Cardiovasc Electrophysiol 20: 153-158.
20. Blackshear JL, Pearce LA, Hart RG et al (1999) Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke 30: 834-840.
21. Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography (1998) Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. Ann Intern Med 128: 639-647.
22. Investigators I-GISSI-AF, Disertori M, Latini R, Barlera S et al (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360: 1606-1617.
23. Marini C, De Santis F, Sacco S et al (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36: 1115-1119.
24. Akar JG, Jeske W, Wilber DJ (2008) Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol 51: 1790-1793.
25. Li-Saw-Hee FL, Blann AD, Gurney D et al (2001) Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 22: 1741-1747.
26. Sohara H, Amitani S, Kurose M et al (1997) Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 29: 106-112.
27. Choudhury A, Chung I, Blann AD et al (2007) Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest 131: 809-815.
28. Ferro D, Loffredo L, Polimeni L et al (2007) Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol 27: 2763-2768.
29. Hart RG, Benavente O, McBride R et al (1999) Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 131: 492-501.